Karyopharm Therapeutics affirms FY2026 sales guidance at $130M-$150M
Karyopharm Therapeutics (NASDAQ: KPTI) affirms FY2026 sales guidance of $130.000 million-$150.000 million versus a $133.736 million estimate, keeping the same range.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.